A deal in the next month and a half would be good. Otherwise I might start getting worried.
I'll be happy with any deal that provides enough up front for them to avoid any more capital raisings and keep the rest of the product pipeline moving, but I think there's a chance it could be a quite significant sum. KV (over)paid Vivus US$150 million for Evamist, but that kind of sum actually seems reasonable for Axiron.
acrux update /bioshares, page-5
Add ACR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.86M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 40561 | 5.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.7¢ | 141 | 1 |
View Market Depth
| Last trade - 16.12pm 14/10/2024 (20 minute delay) ? |
| ACR (ASX) Chart |
Day chart unavailable